Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Polycystic Kidney Disease, Autosomal Recessive.

Sweeney WE, Avner ED.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2001 Jul 19 [updated 2019 Feb 14].

2.

Unique interstitial miRNA signature drives fibrosis in a murine model of autosomal dominant polycystic kidney disease.

Patil A, Sweeney WE Jr, Pan CG, Avner ED.

World J Nephrol. 2018 Sep 7;7(5):108-116. doi: 10.5527/wjn.v7.i5.108. Review.

3.

Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease.

Sweeney WE, Frost P, Avner ED.

World J Nephrol. 2017 Jul 6;6(4):188-200. doi: 10.5527/wjn.v6.i4.188.

4.

Emerging Therapies for Childhood Polycystic Kidney Disease.

Sweeney WE Jr, Avner ED.

Front Pediatr. 2017 Apr 19;5:77. doi: 10.3389/fped.2017.00077. eCollection 2017. Review.

5.

Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy.

Sweeney WE Jr, Avner ED.

Pediatr Res. 2014 Jan;75(1-2):148-57. doi: 10.1038/pr.2013.191. Epub 2013 Oct 31. Review.

6.

Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts.

Fan LX, Zhou X, Sweeney WE Jr, Wallace DP, Avner ED, Grantham JJ, Li X.

J Am Soc Nephrol. 2013 Dec;24(12):2010-22. doi: 10.1681/ASN.2013020176. Epub 2013 Aug 29.

7.

Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease.

Zhou X, Fan LX, Sweeney WE Jr, Denu JM, Avner ED, Li X.

J Clin Invest. 2013 Jul;123(7):3084-98. doi: 10.1172/JCI64401. Epub 2013 Jun 17.

8.

G-protein signaling modulator 1 deficiency accelerates cystic disease in an orthologous mouse model of autosomal dominant polycystic kidney disease.

Kwon M, Pavlov TS, Nozu K, Rasmussen SA, Ilatovskaya DV, Lerch-Gaggl A, North LM, Kim H, Qian F, Sweeney WE Jr, Avner ED, Blumer JB, Staruschenko A, Park F.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21462-7. doi: 10.1073/pnas.1216830110. Epub 2012 Dec 10.

9.

HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells.

Liu W, Fan LX, Zhou X, Sweeney WE Jr, Avner ED, Li X.

PLoS One. 2012;7(11):e49418. doi: 10.1371/journal.pone.0049418. Epub 2012 Nov 13.

10.

Role of genetic modifiers in an orthologous rat model of ARPKD.

O'Meara CC, Hoffman M, Sweeney WE Jr, Tsaih SW, Xiao B, Jacob HJ, Avner ED, Moreno C.

Physiol Genomics. 2012 Aug 1;44(15):741-53. doi: 10.1152/physiolgenomics.00187.2011. Epub 2012 Jun 5.

11.

Transport, cilia, and PKD: must we in (cyst) on interrelationships? Focus on "Increased Na+/H+ exchanger activity on the apical surface of a cilium-deficient cortical collecting duct principal cell model of polycystic kidney disease".

Avner ED, McDonough AA, Sweeney WE Jr.

Am J Physiol Cell Physiol. 2012 May 15;302(10):C1434-5. doi: 10.1152/ajpcell.00070.2012. Epub 2012 Mar 7. No abstract available.

12.

Loss of activator of G-protein signaling 3 impairs renal tubular regeneration following acute kidney injury in rodents.

Regner KR, Nozu K, Lanier SM, Blumer JB, Avner ED, Sweeney WE Jr, Park F.

FASEB J. 2011 Jun;25(6):1844-55. doi: 10.1096/fj.10-169797. Epub 2011 Feb 22.

13.

Diagnosis and management of childhood polycystic kidney disease.

Sweeney WE Jr, Avner ED.

Pediatr Nephrol. 2011 May;26(5):675-92. doi: 10.1007/s00467-010-1656-1. Epub 2010 Oct 29. Review.

PMID:
21046169
14.

Activator of G protein signaling 3 promotes epithelial cell proliferation in PKD.

Nadella R, Blumer JB, Jia G, Kwon M, Akbulut T, Qian F, Sedlic F, Wakatsuki T, Sweeney WE Jr, Wilson PD, Lanier SM, Park F.

J Am Soc Nephrol. 2010 Aug;21(8):1275-80. doi: 10.1681/ASN.2009121224. Epub 2010 May 20.

15.

Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.

Jia G, Kwon M, Liang HL, Mortensen J, Nilakantan V, Sweeney WE, Park F.

Pediatr Nephrol. 2010 Jun;25(6):1139-46. doi: 10.1007/s00467-010-1477-2. Epub 2010 Mar 13.

PMID:
20229187
16.

Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.

Park F, Sweeney WE Jr, Jia G, Akbulut T, Mueller B, Falck JR, Birudaraju S, Roman RJ, Avner ED.

Am J Physiol Renal Physiol. 2009 Mar;296(3):F575-82. doi: 10.1152/ajprenal.90705.2008. Epub 2009 Jan 7. Erratum in: Am J Physiol Renal Physiol. 2009 Oct;297(4):F1135.

17.

20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease.

Park F, Sweeney WE, Jia G, Roman RJ, Avner ED.

J Am Soc Nephrol. 2008 Oct;19(10):1929-39. doi: 10.1681/ASN.2007070771. Epub 2008 Jul 2.

18.

Src inhibition ameliorates polycystic kidney disease.

Sweeney WE Jr, von Vigier RO, Frost P, Avner ED.

J Am Soc Nephrol. 2008 Jul;19(7):1331-41. doi: 10.1681/ASN.2007060665. Epub 2008 Apr 2.

19.

Renal cystic disease: new insights for the clinician.

Avner ED, Sweeney WE Jr.

Pediatr Clin North Am. 2006 Oct;53(5):889-909, ix. Review.

PMID:
17027616
20.

Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD).

Sweeney WE Jr, Avner ED.

Cell Tissue Res. 2006 Dec;326(3):671-85. Epub 2006 Jun 10. Review.

PMID:
16767405
21.

Haplotype analysis improves molecular diagnostics of autosomal recessive polycystic kidney disease.

Consugar MB, Anderson SA, Rossetti S, Pankratz VS, Ward CJ, Torra R, Coto E, El-Youssef M, Kantarci S, Utsch B, Hildebrandt F, Sweeney WE, Avner ED, Torres VE, Cunningham JM, Harris PC.

Am J Kidney Dis. 2005 Jan;45(1):77-87.

PMID:
15696446
22.

Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.

Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, Avner ED.

Kidney Int. 2004 Nov;66(5):1766-73.

23.

EGF-related growth factors in the pathogenesis of murine ARPKD.

MacRae Dell K, Nemo R, Sweeney WE Jr, Avner ED.

Kidney Int. 2004 Jun;65(6):2018-29.

24.

EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.

Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, Avner ED.

Kidney Int. 2003 Nov;64(5):1573-9.

25.

Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability.

Sweeney WE Jr, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED.

Kidney Int. 2003 Oct;64(4):1310-9.

26.

Phenotypic analysis of conditionally immortalized cells isolated from the BPK model of ARPKD.

Sweeney WE Jr, Kusner L, Carlin CR, Chang S, Futey L, Cotton CU, Dell KM, Avner ED.

Am J Physiol Cell Physiol. 2001 Nov;281(5):C1695-705.

27.

A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.

Dell KM, Nemo R, Sweeney WE Jr, Levin JI, Frost P, Avner ED.

Kidney Int. 2001 Oct;60(4):1240-8.

28.

Can progression of autosomal dominant or autosomal recessive polycystic kidney disease be prevented?

Davis ID, MacRae Dell K, Sweeney WE, Avner ED.

Semin Nephrol. 2001 Sep;21(5):430-40. Review.

PMID:
11559884
29.

Expression of the orpk disease gene during kidney development and maturation.

Nakanishi K, Sweeney WE Jr, Avner ED, Murcia NS.

Pediatr Nephrol. 2001 Mar;16(3):219-26.

PMID:
11322368
30.

Role of CFTR in autosomal recessive polycystic kidney disease.

Nakanishi K, Sweeney WE Jr, Macrae Dell K, Cotton CU, Avner ED.

J Am Soc Nephrol. 2001 Apr;12(4):719-25.

31.

Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice.

Nakanishi K, Gattone VH 2nd, Sweeney WE, Avner ED.

Pediatr Nephrol. 2001 Jan;16(1):45-50.

PMID:
11198603
32.

Generation and phenotype of cell lines derived from CF and non-CF mice that carry the H-2K(b)-tsA58 transgene.

Takacs-Jarrett M, Sweeney WE, Avner ED, Cotton CU.

Am J Physiol Cell Physiol. 2001 Jan;280(1):C228-36.

33.

Proximal tubular cysts in fetal human autosomal recessive polycystic kidney disease.

Nakanishi K, Sweeney WE Jr, Zerres K, Guay-Woodford LM, Avner ED.

J Am Soc Nephrol. 2000 Apr;11(4):760-3.

34.

Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.

Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED.

Kidney Int. 2000 Jan;57(1):33-40.

35.

Cellular pathophysiology of cystic kidney disease: insight into future therapies.

Avner ED, Woychik RP, Dell KM, Sweeney WE.

Int J Dev Biol. 1999;43(5):457-61. Review.

36.

In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor.

Sweeney WE, Futey L, Frost P, Avner ED.

Kidney Int. 1999 Aug;56(2):406-13.

37.

New insights into the molecular pathophysiology of polycystic kidney disease.

Murcia NS, Sweeney WE Jr, Avner ED.

Kidney Int. 1999 Apr;55(4):1187-97. Review.

38.

Morphological and functional characterization of a conditionally immortalized collecting tubule cell line.

Takacs-Jarrett M, Sweeney WE, Avner ED, Cotton CU.

Am J Physiol. 1998 Nov;275(5):F802-11. doi: 10.1152/ajprenal.1998.275.5.F802.

PMID:
9815138
39.

Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease.

Sweeney WE Jr, Avner ED.

Am J Physiol. 1998 Sep;275(3):F387-94. doi: 10.1152/ajprenal.1998.275.3.F387.

PMID:
9729511
40.

The role of hepatocyte growth factor (HGF) at progressive stages of metanephric development.

Sweeney WE Jr, Avner ED.

In Vitro Cell Dev Biol Anim. 1998 Feb;34(2):189-94.

PMID:
9542659
41.

Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease.

Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, Avner ED.

J Clin Invest. 1998 Mar 1;101(5):935-9.

42.

Efficacy of taxol in the orpk mouse model of polycystic kidney disease.

Sommardahl CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JE.

Pediatr Nephrol. 1997 Dec;11(6):728-33.

PMID:
9438653
43.

Differential rescue of the renal and hepatic disease in an autosomal recessive polycystic kidney disease mouse mutant. A new model to study the liver lesion.

Yoder BK, Richards WG, Sommardahl C, Sweeney WE, Michaud EJ, Wilkinson JE, Avner ED, Woychik RP.

Am J Pathol. 1997 Jun;150(6):2231-41.

44.

Functional correction of renal defects in a mouse model for ARPKD through expression of the cloned wild-type Tg737 cDNA.

Yoder BK, Richards WG, Sommardahl C, Sweeney WE, Michaud EJ, Wilkinson JE, Avner ED, Woychik RP.

Kidney Int. 1996 Oct;50(4):1240-8.

45.

Novel Madin Darby canine kidney cell clones exhibit unique phenotypes in response to morphogens.

Orellana SA, Neff CD, Sweeney WE, Avner ED.

In Vitro Cell Dev Biol Anim. 1996 Jun;32(6):329-39.

PMID:
8842747
46.

Insertional mutagenesis and molecular analysis of a new gene associated with polycystic kidney disease.

Yoder BK, Richards WG, Sweeney WE, Wilkinson JE, Avener ED, Woychik RP.

Proc Assoc Am Physicians. 1995 Oct;107(3):314-23.

PMID:
8608416
47.

1 alpha, 25-dihydroxyvitamin D3 receptor ontogenesis in fetal renal development.

Johnson JA, Grande JP, Roche PC, Sweeney WE Jr, Avner ED, Kumar R.

Am J Physiol. 1995 Sep;269(3 Pt 2):F419-28.

PMID:
7573491
48.
49.

Tyrosine kinase activity of the EGF receptor in murine metanephric organ culture.

Pugh JL, Sweeney WE Jr, Avner ED.

Kidney Int. 1995 Mar;47(3):774-81.

50.

Epidermal growth factor receptor expression is abnormal in murine polycystic kidney.

Orellana SA, Sweeney WE, Neff CD, Avner ED.

Kidney Int. 1995 Feb;47(2):490-9.

Supplemental Content

Loading ...
Support Center